UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer

Annals of oncology, 2006-08, Vol.17 (8), p.1263-1268

2006

Volltextzugriff (PDF)

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2055-2062

2012

Volltextzugriff (PDF)

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Journal of clinical oncology, 2012-03, Vol.30 (9), p.921-929

2012

Volltextzugriff (PDF)

Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3611-3619

2009

Volltextzugriff (PDF)

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3107-3114

2010

Volltextzugriff (PDF)

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5960-5972

2005

Volltextzugriff (PDF)

Assessing the impact of chart design and time intervals on the usability of time series data visualization: A Case Study on Cryptocurrency Data

SHS web of conferences, 2024, Vol.189, p.1040

2024

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4522-4529

2009

Volltextzugriff (PDF)

Phase II Trial of Nab -Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

Clinical breast cancer, 2012-10, Vol.12 (5), p.313-321

2012

Volltextzugriff (PDF)

Development of a new G-CSF product based on biosimilarity assessment

Annals of oncology, 2010-07, Vol.21 (7), p.1419-1429

2010

Volltextzugriff (PDF)

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Journal of clinical oncology, 2009-02, Vol.27 (4), p.526-534

2009

Volltextzugriff (PDF)

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2010-06, Vol.5 (6), p.852-861

2010

Volltextzugriff (PDF)

Peripheric primitive neuroectodermal tumor (Askin)

Vestnik travmatologii i ortopedii im. N.N. Priorova, 2022-03, Vol.6 (2), p.54-62

2022

Volltextzugriff (PDF)

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Journal of clinical oncology, 2015-02, Vol.33 (5), p.433-441

2015

Volltextzugriff (PDF)

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

European journal of cancer (1990), 2013-12, Vol.49 (18), p.3831-3838

2013

Volltextzugriff (PDF)

Abstract P4-12-08: Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-08

2013

Volltextzugriff (PDF)

Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-13

2017

Volltextzugriff (PDF)

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients

European journal of cancer (1990), 2011, Vol.47, p.S345-S345

2011

Volltextzugriff (PDF)

Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3097-3097

2011

Volltextzugriff (PDF)

Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.9019-9019

2011

Volltextzugriff (PDF)

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-19-13

2011

Volltextzugriff (PDF)

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-19-03

2011

Volltextzugriff (PDF)

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.275-275

2011

Volltextzugriff (PDF)

Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC)

JOURNAL OF CLINICAL ONCOLOGY, 2010, Vol.28 (18_suppl), p.LBA1010-LBA1010

2010

Volltextzugriff (PDF)

First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.571-571

2011

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(61)
Tagungsberichte
(1)

Sprache

Englisch
(47)
Russisch
(17)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Assessing the impact of chart design and time intervals on the usability of time series data visualization: A Case Study on Cryptocurrency Data

Phase II Trial of Nab -Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

Development of a new G-CSF product based on biosimilarity assessment

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Peripheric primitive neuroectodermal tumor (Askin)

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

Abstract P4-12-08: Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients

Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors

Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC)

First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC

Suchergebnisse filtern